At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 582 enrolled
Drug / intervention
Ranibizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration
In Brief
A Phase 3 clinical trial evaluating Ranibizumab for Macular Degeneration. Completed, enrolled 582 participants across 102 sites in 15 countries.
Detailed Summary
The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesBulgaria, Czechia, Estonia, Hungary, India, Israel, Latvia, Lithuania, Poland, Romania, Russia, Slovakia, Spain, Ukraine, United States
CollaboratorsStada Arzneimittel AG
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartApr 2019
Primary CompletionMay 2021
Study CompletionNov 2021
TodayJul 2026
First PostedJan 15, 2019
Enrollment StartApr 19, 2019
Primary CompletionMay 11, 2021
Study CompletionNov 11, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.5 years ago
Interventions
Ranibizumabbiological
Intravitreal injection